Company2019-06-13T03:07:28+00:00

About ProLung

ProLung is a medical technology company specializing in innovative predictive analytics technology and non-invasive test for the risk stratification of indeterminate pulmonary nodules that can lead to lung cancer. The rapid, non-invasive, and radiation-free ProLung Test™ was developed to rapidly assess the risk of malignancy in lung nodules found in the chest. Currently, patients typically wait between three months and three and one-half years to have the risk of malignancy assessed through periodic CT scans. Until malignancy is determined to be likely, invasive biopsy and treatment may be significantly delayed. The ProLung Test can be completed in fewer than 30 minutes and can provide results within 24 hours. 

According to the American Cancer Society and the American Lung Association, lung cancer is the leading cause of cancer death among both men and women; about one out of four cancer deaths are from lung cancer.1 They estimate that in 2017, more people in the United States will die of lung cancer than of colon, breast, and prostate cancers combined.2 Until recently, asymptomatic lung cancer was detected only incidentally.3 Currently, a lung cancer screen now reimbursed by Medicare, is performed by low-dose computed tomography.4  This may lead to a dramatic increase in the number of individuals with lung nodules detected, which is intensifying the need for a risk stratification test such as the ProLung Test.

1 American Lung Association (ALA) (full text)
2 American Cancer Society (ACS) (full text)
3 National Lung Screening Trial Research Team (NLST). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365:395-409 (full text)
4 Centers for Medicare & Medicaid Services (full text)

Our mission is to make a difference in time by striving to improve outcomes for potential lung cancer patients through early predictive technologies; provide cost savings to patients, payers, and providers; and to provide a fair return on investment to shareholders and other stakeholders.

ProLung is committed to making a positive and significant impact on the healthcare community and to being socially responsible in all its endeavors.

The Company has adopted the Code of Ethics for Senior Executives, Financial Officers, Members of the Management Executive Committee, and Directors, which constitutes a code of ethics that applies to the principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions, as defined in Item 406 of Regulation S-K under the Exchange Act.

Meet Our Team

Jared Bauer
 Interim CEO and Independent Director

Mr. Bauer was appointed interim CEO in September 2018. He is also the Chief Executive Officer of ApolloDx, LLC, an in vitro mobile point-of-care diagnostic company, and the Chief Executive Officer of CibusDx Inc., a company delivering technology that improves food safety testing. In 2012, Mr. Bauer previously founded Exuro Medical and acquired BurnFree Products. In just two years with a focus on sustainable revenue generation, he led the Exuro Medical team to expand BurnFree distribution to 58 countries, managing regulatory processes, re-working quality systems and making BurnFree the second largest burn treatment product line in the world. Mr. Bauer currently serves as a trustee at The Oliver Fund, which is a non-profit he co-founded, and recently served as an adjunct professor of entrepreneurship at the LDS Business College.

Michael A. Garff
COO and Director

Mr. Garff joined ProLung as the Chief Operating Officer in June 2009. At ProLung, he obtained European regulatory approval (CE Mark), organized and operates manufacturing, acquired clinical sites at premier cancer hospitals, and designed and implemented a certified ISO 13485 quality management system. Currently, he oversees ProLung’s product development, manufacturing, clinical studies, regulatory affairs, FDA submissions, quality audits, data analysis, and patents. Prior to ProLung, he was involved with the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped launch several biomedical companies. Previously, Mr. Garff also earned a reputation as an organization builder and effective project manager at the Biomedical Informatics Department of the University of Utah and US Bank. His commercialization experience and entrepreneurial attitude towards challenges gives him uncommon perspective in developing technology into products and creating successful companies. He holds a BS in Business Finance and an MBA from the University of Utah.

Rex Chin-Wei Yung, MD, FCCP
Chief Medical Officer

Mr. Rex Chin-Wei Yung, MD, FCCP, has been with ProLung full-time since 2017. As the Chief Medical Officer, he leads the evaluation of opportunities to expand our underlying science and indications through his expertise in translational research of lung cancer biomarkers and early cancer detection through imaging and bronchoscopy. Previously, Dr. Yung was the Chief Scientific Officer at ProLung. Previous to that, Dr. Yung was the Director of Pulmonary Oncology and Director of Bronchoscopy at Johns Hopkins University School of Medicine (JHU). Dr. Yung remains an adjunct faculty in the Department of Oncology at JHU. Dr. Yung is a fellow of the American College of Chest Physicians. He is board certified in Internal Medicine, Pulmonary and Critical Care Medicine and has served on the executive and editorial boards of the American Association of Bronchology and Interventional Pulmonology and Journal of Bronchology and Interventional Pulmonology. Dr. Yung earned a Bachelor of Arts from Harvard University and his MD from the University of California at Los Angeles (UCLA).

Andy C. Robertson
Vice President of Business Development

Mr. Robertson joined ProLung in July 2017 and is focused on identifying mutually beneficial strategic partnerships, establishing and strengthening relationships with sales distribution partners, gaining reimbursement and utilizing ProLung’s CE mark. Over the course of more than 20 years in the global medical device or medtech industry, he has held upstream and downstream marketing positions of increasing responsibility, been publicly recognized with marketing awards and launched 15 medical devices. He brings an invaluable professional perspective and organizational savvy from his tenure with smaller medical device manufacturers (Utah Medical Products and Megadyne now J&J Ethicon) to some of the largest (Covidien now Medtronic, Becton Dickinson and CR Bard). He holds a Bachelor of Science in Marketing from the University of Utah. In particular, Mr. Robertson has a proven track record of profitably delivering what health care providers and patients want.

Board of Directors

Robert Raybould, Member of ProLung Board of Directors

Robert W. Raybould
Vice Chair of the Board, Director

Mr. Raybould serves as a Director of ProLung. He began his career serving in the U.S. Army and then with Eastman Kodak in Rochester, New York. He then co-founded Realvest, a real estate investment company. Mr. Raybould has helped found several financial companies including TRI Capital Corporation, DTM Research, and Greenhill Financial, which became Arlington Value Capital, LLC. Mr. Raybould holds a BS in Banking and Finance as well as an MBA from the University of Utah.

Jared Bauer
Independent Director and Interim CEO

Mr. Bauer was appointed interim CEO in September 2018. He is also the Chief Executive Officer of ApolloDx, LLC, an in vitro mobile point-of-care diagnostic company, and the Chief Executive Officer of CibusDx Inc., a company delivering technology that improves food safety testing. In 2012, Mr. Bauer previously founded Exuro Medical and acquired BurnFree Products. In just two years with a focus on sustainable revenue generation, he led the Exuro Medical team to expand BurnFree distribution to 58 countries, managing regulatory processes, re-working quality systems and making BurnFree the second largest burn treatment product line in the world. Mr. Bauer currently serves as a trustee at The Oliver Fund, which is a non-profit he co-founded, and recently served as an adjunct professor of entrepreneurship at the LDS Business College.

Don A. Patterson 
Director

Mr. Don Patterson joined the Board in mid-2019. He began his professional career in public accounting and worked for both large and small firms as a CPA for 24 years. During this time, he developed expertise in financial analysis and was significantly involved in merger and acquisition (M&A) activities. He has been involved in multiple boards of directors for companies ranging in size from small, closely-held companies to large privately-held, publicly listed companies. He has been one of the founders in various entrepreneurial ventures, including manufacturing, distribution, intellectual property (IP) development and prosecution. His primary pursuit for the past 19 years has been in the development and licensing of patents involving manufacturing processes used in the home products industry. Mr. Patterson currently resides in Gilbert, Arizona and holds a BA degree in accounting from Arizona State University.

Michael Garff, member of ProLung Board of Drectors

Michael A. Garff 
Director and COO

Mr. Garff joined ProLung as the Chief Operating Officer in June 2009. At ProLung, he obtained European regulatory approval (CE Mark), organized and operates manufacturing, acquired clinical sites at premier cancer hospitals, and designed and implemented a certified ISO 13485 quality management system. Currently, he oversees ProLung’s product development, manufacturing, clinical studies, regulatory affairs, FDA submissions, quality audits, data analysis, and patents. Prior to ProLung, he was involved with the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped launch several biomedical companies. Previously, Mr. Garff also earned a reputation as an organization builder and effective project manager at the Biomedical Informatics Department of the University of Utah and US Bank. His commercialization experience and entrepreneurial attitude towards challenges gives him uncommon perspective in developing technology into products and creating successful companies. He holds a BS in Business Finance and an MBA from the University of Utah.

Jim Hogan
 Independent Director

Mr. Jim Hogan joined the Board in mid-2019. He served his entire professional career in the medtech industry in multiple locations in the USA and abroad. After rising to the role of Director of Sales and Marketing for Pfizer Europe in London, he successfully founded two medtech companies and led two others. These four start-up medtech companies were all successfully exited. Mr. Hogan recently retired from Medtronic, one of the world’s largest medtech companies where he was President of Medtronic Latin America, corporate Vice President, and appointed to the company’s Sr. Executive Committee. Mr. Hogan has deep operational, sales, marketing, and general management expertise with medical devices and therapeutics in some of the smallest and largest medtech companies in the world. Mr. Hogan remains dedicated to health-related philanthropic endeavors from his home in Park City, Utah. Mr. Hogan holds a BA in Chemistry and Psychology in addition to a MBA from the University of Minnesota.

David Nielsen
 Independent Director

Mr. David Nielsen joined the Board in mid-2019. He has 20 years of R&D and leadership experience at BioFire and BioFire Defense (formerly named Idaho Technology), which sold to bioMérieux in 2014. As one of the original Idaho Technology employees, Mr. Nielsen worked in various roles in engineering, management, and business development rising to the position of Vice President of Product Development. He managed a team of more than 70 scientists and engineers who were responsible for developing and launching new medical diagnostic products and supporting the complex regulatory clearance process in the US, EU, and other countries. Mr. Nielsen is currently a partner at Whiteknob, which is a medtech product development company based in Salt Lake City, Utah. Mr. Nielsen holds a BS degree in Mechanical Engineering from BYU, and a Master of Mechanical Engineering from the University of Utah.